Neovasc (NASDAQ:NVCN) Earns Sell Rating from Analysts at assumed coverage on shares of Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) in a research report released on Monday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, Bloom Burton restated a buy rating on shares of Neovasc in a research note on Friday, August 12th.

Neovasc Trading Up 9.5 %

NVCN stock opened at $7.50 on Monday. Neovasc has a 1-year low of $4.59 and a 1-year high of $20.00. The company has a debt-to-equity ratio of 0.43, a current ratio of 8.44 and a quick ratio of 8.13. The company has a market capitalization of $20.55 million, a price-to-earnings ratio of -0.61 and a beta of 1.96. The business has a 50 day simple moving average of $6.61 and a two-hundred day simple moving average of $6.48.

About Neovasc

(Get Rating)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.

Featured Articles

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.